Search PubMed⌕ Search

Biomedical subjects

B Butler

Publications and source records attributed to B Butler.

At least 37 records · Page 2Linked to original sources
PubMed1996

Initial clinical experience with the Peacock intensity modulation of a 3-D conformal radiation therapy system.

Peacock is a 3-D conformal treatment planning and delivery system for conformal radiation therapy which delivers intensity-modulated fields. A group of 13 patients were treated between March and February, 1995. Patient age ranged from 10 to 74. Six of the patients had previously received radiation therapy. Target volume was from 2.5 to 70 cm3: all treatments were fractionated, using single table angle plan with 270 degrees of rotation. A removable invasive cranial screw fixation device was used in all cases. Treated isodose line averaged 85%; conformality index was better than 2, with 0-5% of critical structure volume exceeding dose limits. Setup time averaged 8 min per fraction: treatment time ranged from 10 to 80 min. There were two equipment failures in 200 fractions/1,000 gantry rotations. Patient position averaged about 1 mm within initial setup. Follow-up has revealed no complications from the radiation.

Adolescent↗
PubMed1995

Design and biological activities of L-163,191 (MK-0677): a potent, orally active growth hormone secretagogue.

A potent, orally active growth hormone (GH) secretagogue L-163,191 belonging to a recently synthesized structural class has been characterized. L-163,191 releases GH from rat pituitary cells in culture with EC50 = 1.3 +/- 0.09 nM and is mechanistically indistinguishable from the GH-releasing peptide GHRP-6 and the prototypical nonpeptide GH secretagogue L-692,429 but clearly distinguishable from the natural GH secretagogue, GH-releasing hormone. L-163,191 elevates GH in dogs after oral doses as low as 0.125 mg/kg and was shown to be specific in its release of GH without significant effect on plasma levels of aldosterone, luteinizing hormone, thyroxine, and prolactin after oral administration of 1 mg/kg. Only modest increases in cortisol were observed. Based on these properties, L-163,191 has been selected for clinical studies.

Administration, Oral↗
PubMed1995

Squamous cell carcinoma complicating idiopathic inflammatory bowel disease.

Squamous cell carcinoma of the colon and rectum, originating proximal to the transitional zone, is a rare complication of idiopathic inflammatory bowel disease (IIBD). To date there are only 15 single case reports of such an occurrence. This carcinoma develops more commonly in females and in patients with pancolonic disease of more than 8 years' duration. The rectum is affected in two thirds of the cases. Squamous cell changes, in the vicinity of the primary adenocarcinoma, are present in 27% of cases. The carcinoma is in a pathologically advanced stage in one third of the cases. Colectomy is the main therapeutic modality. Survival following surgical resection ranged from 7 months to 21 years. We present an additional case of rectal squamous cell carcinoma (SCC) complicating chronic ulcerative colitis in a 33-year-old woman who had the disease for 15 years. Multiple biopsies of a gross lesion located 5 cm above the dendate line were consistent with invasive basaloid cell carcinoma. The patient received 5-FU, mitomycin C, and radiotherapy prior to a proctocolectomy and ileostomy. The only histopathologic finding at pathologic review of the surgical specimen was severe squamous dysplasia.

Adult↗
PubMed1994

A novel 3-substituted benzazepinone growth hormone secretagogue (L-692,429).

The 3-substituted benzazepinone, L-692,429 (compound 1), is the prototype compound of a novel class of compounds that stimulate release of growth hormone (GH). The molecule evolved from efforts to identify a non-peptide mimic of the growth hormone-releasing hexapeptide, GHRP-6. Compound 1 is prepared by sequential attachment of dimethyl-beta-alanine and 2'-biphenylyltetrazole side chains to a chiral 3-aminobenzolactam nucleus. Comparison of the biological activity of 1 with the corresponding six- and eight-membered lactam analogs shows the seven-membered benzazepinone skeleton to be preferred. Molecular modeling of the structurally diverse GH secretagogues, L-692,429 and GHRP-6, was performed.

Amino Acid Sequence↗
PubMed1994

Deaths associated with renal agenesis: a population-based study of birth prevalence, case ascertainment, and etiologic heterogeneity.

We report on deaths associated with renal agenesis among 211,704 consecutive births. Sources included birth and death certificates and an active birth defects surveillance system. Medical review and classification of cases were performed for 1985-1990 events. Sixty-one cases of renal agenesis were identified, and review of records was possible for 59 of the 61 cases. Of these 59 cases, 36 (61%) were confirmed, 5 (8%) were questionable, and 18 (31%) were incorrectly coded. The prevalence of confirmed cases is thus estimated at 17/100,000 births (14.2/100,000 births, excluding elective terminations and fetal deaths). Records incorrectly coded were most often those with multicystic dysplasia. Approximately one-third of cases was found by the birth defects surveillance system alone, confirming the utility of this data source for prevalence estimates. Isolated renal agenesis accounted for 44% of confirmed cases; other diagnoses included VATER association (19%), unrecognized multiple malformation syndromes (17%), exstrophy of the cloaca sequence (14%), and chromosome disorders (6%). Based on these data, prevalence rates for ICD code 753.0 and death include overascertainment of cases from erroneous coding of multicystic dysplasia and underascertainment of cases with unilateral renal agenesis associated with other malformations. Population-based ascertainment of cases by active surveillance methods and rigorous diagnostic coding standards are required to improve the accuracy of these rates. Targeted investigations of distinct subclassifications will be necessary to identify specific etiologic factors.

Humans↗
PubMed1994

Detection of DNA and E7 transcripts of human papillomavirus types 16, 18, 31 and 33, TGF beta and GM-CSF transcripts in cervical cancers and precancers.

The association of human papillomavirus (HPV) with a high proportion of cervical cancers should allow the efficiency of cytological screening methods to be improved. We report here that quantitative detection of HPV types 16, 18, 31 and 33 DNA and the corresponding E7 transcripts by polymerase chain reaction (PCR) may be of value in identifying precancers and cancers. In clinical specimens with major cervical lesions, the level of E7 transcription does not appear to be related to concomitant transcription of either transformation growth factor-beta (TGF beta) or granulocyte-macrophage colony stimulating factor (GM-CSF) genes.

Base Sequence↗
PubMed1994

Nucleic acid sequence analysis software packages.

Software packages have made sequence analysis easier and more accessible to research scientists in many fields. The majority of these packages are routinely upgraded to include improved and innovative programs for primer design, sequence assembly and improvements in database searching programs. The interfaces of many packages have also been improved, greatly facilitating their use. In the future, researchers can expect to be able to access a growing number of network applications (e.g. database searching and exon prediction programs) from within software packages, making them accessible in familiar formats. Increased network access from within software packages will also make more databases, and more frequently updated databases, available to a larger research community.

Base Sequence↗
PubMed1994

Fractionated brachytherapy: catheter insertion and dosimetry.

The incorporation of the Omnitron device, a robotic isotope handling system, into a program of brachytherapy for glial tumors has made it possible to hyperfractionate treatment in 15-20 sessions over a 2- to 3-week period, which offers considerable theoretical advantage over conventional single dose regimens. Stereotactic catheter placement is by contrast-enhanced MR guidance, and takes advantage of the three-dimensional planning offered by voxel orientation. Initial placement is based on orientation to the three customary planes, with oblique planes added to define intercatheter placement more accurately. Catheters may be placed asymmetrically through the tumor or even at different angles of insertion to get the optimal conformation. Dosimetry is based on three-dimensional reconstruction in the Omnitron planning console, and takes advantage of the optimized localization of each catheter position. High-dose isotope insertion is performed robotically, with isotope position and dwell times controlled by computer. The phase I study demonstrates a wide safety margin and suggests better survival than would be expected with conventional management.

Brachytherapy↗
PubMed1993

Pituitary adenylate cyclase activating polypeptide-induced desensitization on growth hormone release from rat primary pituitary cells.

Pituitary adenylate cyclase activating polypeptide (PACAP38) stimulated growth hormone release as well as cAMP accumulation in a static rat primary pituitary cell culture in a dose-dependent manner with EC50 values of 1.9 +/- 0.4 nM (n = 13) and 0.9 +/- 0.3 nM (n = 5), respectively. The maximal GH response was observed between 5 to 15 min. Prolonged incubation (3 to 4 hrs) markedly reduced the stimulatory effect of PACAP38. The effect of PACAP38 on GH release was desensitized by pretreatment of the cells with PACAP38 or GRF, but not with PMA. The PACAP38-induced desensitization appeared to be time- and dose-dependent. Somatostatin (20 nM) inhibited PACAP-stimulated GH release through a cAMP-independent pathway.

Animals↗